Abstract
Understanding the natural history of coronary artery atherosclerosis is necessary to determine prognosis and prescribe effective therapies. Traditional management of coronary artery disease has focused on the treatment of flow-limiting anatomical obstructions that lead to ischaemia. In most scenarios, revascularization of these atherosclerotic plaques has not substantially improved freedom from death or myocardial infarction, questioning the utility of contemporary revascularization strategies to improve prognosis. Advances in non-invasive and invasive imaging techniques have helped to identify the characteristics of obstructive and non-obstructive plaques that are precursors for plaque progression and future acute coronary syndromes as well as cardiac death. These ‘vulnerable plaques’ develop as a consequence of systemic inflammation and are prone to inducing thrombosis. Vulnerable plaques most commonly have a large plaque burden with a well-formed necrotic core and thin fibrous cap and are metabolically active. Perivascular adipose tissue might, in some patients, be used as a surrogate for coronary inflammation and predict future risk of adverse cardiac events. Vulnerable plaques can be identified in their quiescent state, offering the potential for therapeutic passivation. In this Review, we describe the biological and compositional features of vulnerable plaques, the non-invasive and invasive diagnostic modalities to characterize vulnerable plaques, the prognostic utility of identifying vulnerable plaques, and the future studies needed to explore the value of intensified pharmacological and focal treatments of vulnerable plaques.
Key points
-
Vulnerable plaques are atherosclerotic coronary lesions prone to thrombosis owing to their specific structure and biological and chemical features.
-
Non-invasive and invasive diagnostic modalities, including CT angiography and catheter-based imaging techniques, have been developed to detect these lesions before they cause adverse cardiovascular events.
-
Pharmacological and interventional treatments of vulnerable plaques have been shown to favourably alter the mechanical structure and composition of vulnerable plaques, which might lead to plaque stabilization and improve clinical outcomes.
-
Future large-scale, randomized, controlled clinical trials are needed to explore the value of intensified pharmacological and focal treatments of high-risk vulnerable plaques in vulnerable patients, that is, those patients who have an increased risk of cardiac events.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Khan, M. A. et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus 12, e9349 (2020).
Alderman, E. L. et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J. Am. Coll. Cardiol. 22, 1141–1154 (1993).
Maddox, T. M. et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA 312, 1754–1763 (2014).
The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360, 2503–2515 (2009).
Boden, W. E. et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356, 1503–1516 (2007).
Maron, D. J. et al. Initial invasive or conservative strategy for stable coronary disease. N. Engl. J. Med. 382, 1395–1407 (2020).
Bangalore, S., Maron, D. J., Stone, G. W. & Hochman, J. S. Routine revascularization versus initial medical therapy for stable ischemic heart disease. Circulation 142, 841–857 (2020).
Sorbets, E. et al. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. Eur. Heart J. 41, 347–356 (2020).
Kedhi, E. et al. Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial. Eur. Heart J. 42, 4671–4679 (2021).
Lee, J. M. et al. Prognostic implications of plaque characteristics and stenosis severity in patients with coronary artery disease. J. Am. Coll. Cardiol. 73, 2413–2424 (2019).
Muller, J. E., Tofler, G. H. & Stone, P. H. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 79, 733–743 (1989).
Liang, M., Puri, A. & Devlin, G. The vulnerable plaque: the real villain in acute coronary syndromes. Open. Cardiovasc. Med. J. 5, 123–129 (2011).
Arnold, S. V. et al. Adherence to guideline medication recommendations to prevent atherosclerotic cardiovascular disease progression among adults with prior myocardial infarction. JAMA Netw. Open 3, e203032 (2020).
Knuuti, J. et al. 2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes. Eur. Heart J. 41, 407–477 (2020).
Arnett, D. K. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation https://doi.org/10.1161/CIR.0000000000000678 (2019).
Emond, M. et al. Long-term survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 90, 2645–2657 (1994).
Bergmark, B. A. & Morrow, D. A. Beyond the ISCHEMIA trial: revascularization for stable ischemic heart disease in patients with high-risk coronary anatomical features. J. Am. Heart Assoc. 10, e019974 (2021).
Bainey, K. R. et al. Long-term clinical outcomes following revascularization in high-risk coronary anatomy patients with stable ischemic heart disease. J. Am. Heart Assoc. 10, e018104 (2021).
Yusuf, S. et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344, 563–570 (1994).
Cortigiani, L. et al. Prediction of mortality by stress echocardiography in 2835 diabetic and 11305 nondiabetic patients. Circ. Cardiovasc. Imaging 8, e002757 (2015).
Dorbala, S. et al. Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. J. Am. Coll. Cardiol. 61, 176–184 (2013).
Patel, K. K. et al. Myocardial blood flow reserve assessed by positron emission tomography myocardial perfusion imaging identifies patients with a survival benefit from early revascularization. Eur. Heart J. 41, 759–768 (2020).
Hachamovitch, R., Hayes, S. W., Friedman, J. D., Cohen, I. & Berman, D. S. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 107, 2900–2907 (2003).
Zimmermann, F. M. et al. Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial. Eur. Heart J. 36, 3182–3188 (2015).
Gersh, B. J. et al. To stent or not to stent? Treating angina after ISCHEMIA-introduction. Eur. Heart J. 42, 1387–1388 (2021).
Reynolds, H. R. et al. Outcomes in the ISCHEMIA trial based on coronary artery disease and ischemia severity. Circulation 144, 1024–1038 (2021).
Lopes, R. D. et al. Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction. Circulation 142, 1725–1735 (2020).
Gersh, B. J. & Bhatt, D. L. To stent or not to stent? Treating angina after ISCHEMIA-the impact of the ISCHEMIA trial on the indications for angiography and revascularization in patients with stable coronary artery disease. Eur. Heart J. 42, 1389–1393 (2021).
Head, S. J. et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 391, 939–948 (2018).
Lee, C. W. et al. Coronary artery bypass surgery versus drug-eluting stent implantation for left main or multivessel coronary artery disease: a meta-analysis of individual patient data. JACC Cardiovasc. Interv. 9, 2481–2489 (2016).
Sabatine, M. S. et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet 398, 2247–2257 (2021).
Taqueti, V. R. et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation 131, 19–27 (2015).
Finn, A. V., Nakano, M., Narula, J., Kolodgie, F. D. & Virmani, R. Concept of vulnerable/unstable plaque. Arterioscler. Thromb. Vasc. Biol. 30, 1282–1292 (2010).
Virmani, R., Burke, A. P., Farb, A. & Kolodgie, F. D. Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 47 (Suppl. 8), C13–C18 (2006).
Arbab-Zadeh, A. & Fuster, V. From detecting the vulnerable plaque to managing the vulnerable patient: JACC state-of-the-art review. J. Am. Coll. Cardiol. 74, 1582–1593 (2019).
Burke, A. P. et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103, 934–940 (2001).
Burke, A. P. et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N. Engl. J. Med. 336, 1276–1282 (1997).
Stone, G. W. et al. A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 364, 226–235 (2011).
Calvert, P. A. et al. Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in vulnerable atherosclerosis) study. JACC Cardiovasc. Imaging 4, 894–901 (2011).
Fleg, J. L. et al. Detection of high-risk atherosclerotic plaque. JACC Cardiovasc. Imaging 5, 941–955 (2012).
Wentzel, J. J. et al. Endothelial shear stress in the evolution of coronary atherosclerotic plaque and vascular remodelling: current understanding and remaining questions. Cardiovasc. Res. 96, 234–243 (2012).
Stone, P. H. et al. Prediction of progression of coronary artery disease and clinical outcomes using vascular profiling of endothelial shear stress and arterial plaque characteristics. Circulation 126, 172–181 (2012).
Libby, P. Lipoprotein (a): a frustrating final frontier in lipid management? JACC Basic. Transl. Sci. 1, 428–431 (2016).
Deb, A. & Caplice, N. M. Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin. Cardiol. 27, 258–264 (2004).
Kim, H. W., Shi, H., Winkler, M. A., Lee, R. & Weintraub, N. L. Perivascular adipose tissue and vascular perturbation/atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 40, 2569–2576 (2020).
Antoniades, C., Antonopoulos, A. S. & Deanfield, J. Imaging residual inflammatory cardiovascular risk. Eur. Heart J. 41, 748–758 (2020).
Libby, P. & Lee, R. T. Matrix matters. Circulation 102, 1874–1876 (2000).
Deguchi, J. O. et al. Inflammation in atherosclerosis. Circulation 114, 55–62 (2006).
Sukhova, G. K. et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 99, 2503–2509 (1999).
Wang, J. et al. High fluid shear stress prevents atherosclerotic plaque formation by promoting endothelium denudation and synthetic phenotype of vascular smooth muscle cells. Mol. Med. Rep. 24, 577 (2021).
Ambrose, J. A. et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J. Am. Coll. Cardiol. 12, 56–62 (1988).
Glaser, R. et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 111, 143–149 (2005).
Aguirre, A. D., Arbab-Zadeh, A., Soeda, T., Fuster, V. & Jang, I. K. Optical coherence tomography of plaque vulnerability and rupture. J. Am. Coll. Cardiol. 78, 1257–1265 (2021).
Motoyama, S. et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J. Am. Coll. Cardiol. 50, 319–326 (2007).
Shmilovich, H. et al. Vulnerable plaque features on coronary CT angiography as markers of inducible regional myocardial hypoperfusion from severe coronary artery stenoses. Atherosclerosis 219, 588–595 (2011).
Puchner, S. B. et al. High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial. J. Am. Coll. Cardiol. 64, 684–692 (2014).
Kröner, E. S. J. et al. Positive remodeling on coronary computed tomography as a marker for plaque vulnerability on virtual histology intravascular ultrasound. Am. J. Cardiol. 107, 1725–1729 (2011).
Maehara, A. & Stone, G. W. High-risk coronary atherosclerosis. Circ. Cardiovasc. Imaging 10, e007116 (2017).
Motoyama, S. et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. J. Am. Coll. Cardiol. 66, 337–346 (2015).
Otsuka, K. et al. Prognosis of vulnerable plaque on computed tomographic coronary angiography with normal myocardial perfusion image. Eur. Heart J. Cardiovasc. Imaging 15, 332–340 (2014).
Lee, S. E. et al. Differences in progression to obstructive lesions per high-risk plaque features and plaque volumes with CCTA. JACC Cardiovasc. Imaging 13, 1409–1417 (2020).
Williams, M. C. et al. Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction. Circulation 141, 1452–1462 (2020).
Xie, J. X. et al. Prognostic significance of nonobstructive left main coronary artery disease in women versus men: long-term outcomes from the CONFIRM registry. Circ. Cardiovasc. Imaging 10, e006246 (2017).
Kotanidis, C. P. et al. Pericoronary fat radiomic profile (FRP) predicts long-term cardiac risk in individuals with calcium score below 100 on coronary computed tomography angiography. Eur. Heart J. 41 (Suppl. 2), ehaa946.0181 (2020).
Oikonomou, E. K. et al. Perivascular fat attenuation index stratifies cardiac risk associated with high-risk plaques in the CRISP-CT study. J. Am. Coll. Cardiol. 76, 755–757 (2020).
Oikonomou, E. K. et al. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet 392, 929–939 (2018).
Channon, K. M., Newby, D. E., Nicol, E. D. & Deanfield, J. Cardiovascular computed tomography imaging for coronary artery disease risk: plaque, flow and fat. Heart https://doi.org/10.1136/heartjnl-2021-320265 (2022).
Takaya, N. et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI-initial results. Stroke 37, 818–823 (2006).
Phinikaridou, A. et al. In vivo detection of vulnerable atherosclerotic plaque by MRI in a rabbit model. Circ. Cardiovasc. Imaging 3, 323–332 (2010).
Vancraeynest, D., Pasquet, A., Roelants, V., Gerber, B. L. & Vanoverschelde, J. L. J. Imaging the vulnerable plaque. J. Am. Coll. Cardiol. 57, 1961–1979 (2011).
Asaumi, Y. et al. High-intensity plaques on noncontrast T1-weighted imaging as a predictor of periprocedural myocardial injury. JACC Cardiovasc. Imaging 8, 741–743 (2015).
Noguchi, T. et al. High-intensity signals in coronary plaques on noncontrast T1-weighted magnetic resonance imaging as a novel determinant of coronary events. J. Am. Coll. Cardiol. 63, 989–999 (2014).
Liu, W. et al. Relationship between coronary hyper-intensive plaques identified by cardiovascular magnetic resonance and clinical severity of acute coronary syndrome. J. Cardiovasc. Magn. Reson. 23, 12 (2021).
Matsumoto, K., Ehara, S., Hasegawa, T., Nishimura, S. & Shimada, K. The signal intensity of coronary culprit lesions on T1-weighted magnetic resonance imaging is directly correlated with the accumulation of vulnerable morphologies. Int. J. Cardiol. 231, 284–286 (2017).
Engel, L. C. et al. Novel approach for in vivo detection of vulnerable coronary plaques using molecular 3-T CMR imaging with an albumin-binding probe. JACC Cardiovasc. Imaging 12, 297–306 (2019).
González Ballester, M. A., Zisserman, A. P. & Brady, M. Estimation of the partial volume effect in MRI. Med. Image Anal. 6, 389–405 (2002).
Noguchi, T. et al. Noninvasive coronary plaque imaging. J. Atheroscler. Thromb. 25, 281–293 (2018).
Lairez, O. & Hyafil, F. A clinical role of PET in atherosclerosis and vulnerable plaques? Semin. Nucl. Med. 50, 311–318 (2020).
Strauss, H. W. & Narula, J. Imaging vulnerable plaque. J. Am. Coll. Cardiol. 69, 1792–1794 (2017).
Tarkin, J. M. et al. Detection of atherosclerotic inflammation by 68Ga-DOTATATE PET compared to [18F]FDG PET imaging. J. Am. Coll. Cardiol. 69, 1774–1791 (2017).
Marnane, M. et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann. Neurol. 71, 709–718 (2012).
Kwiecinski, J. et al. Coronary 18F-sodium fluoride uptake predicts outcomes in patients with coronary artery disease. J. Am. Coll. Cardiol. 75, 3061–3074 (2020).
Bourassa, M. G. The history of cardiac catheterization. Can. J. Cardiol. 21, 1011–1014 (2005).
Tonino, P. A. L. et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N. Engl. J. Med. 360, 213–224 (2009).
Götberg, M. et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N. Engl. J. Med. 376, 1813–1823 (2017).
Fearon, W. F. et al. Fractional flow reserve–guided PCI as compared with coronary bypass surgery. N. Engl. J. Med. 386, 128–137 (2022).
Glagov, S., Weisenberg, E., Zarins, C. K., Stankunavicius, R. & Kolettis, G. J. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. 316, 1371–1375 (1987).
Schoenhagen, P. et al. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes. Circulation 101, 598–603 (2000).
Darmoch, F. et al. Intravascular ultrasound imaging–guided versus coronary angiography-guided percutaneous coronary intervention: a systematic review and meta-analysis. J. Am. Heart Assoc. 9, e013678 (2020).
Zheng, B. et al. Predictors of plaque rupture within nonculprit fibroatheromas in patients with acute coronary syndromes: the PROSPECT study. JACC Cardiovasc. Imaging 8, 1180–1187 (2015).
Kotani, J. I. et al. Intravascular ultrasound analysis of infarct-related and non-infarct-related arteries in patients who presented with an acute myocardial infarction. Circulation 107, 2889–2893 (2003).
Suh, W. M., Seto, A. H., Margey, R. J. P., Cruz-Gonzalez, I. & Jang, I. K. Intravascular detection of the vulnerable plaque. Circ. Cardiovasc. Imaging 4, 169–178 (2011).
Bourantas, C. V. et al. Clinical and angiographic characteristics of patients likely to have vulnerable plaques: analysis from the PROSPECT study. JACC Cardiovasc. Imaging 6, 1263–1272 (2013).
McPherson, J. A. et al. Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention. JACC Cardiovasc. Imaging 5, S76–S85 (2012).
Inaba, S. et al. Impact of positive and negative lesion site remodeling on clinical outcomes: insights from PROSPECT. JACC Cardiovasc. Imaging 7, 70–78 (2014).
Jang, I. K. et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. J. Am. Coll. Cardiol. 39, 604–609 (2002).
Kubo, T. et al. Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial): one-year angiographic and clinical results. Eur. Heart J. 38, 3139–3147 (2017).
Tearney, G. J. et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for intravascular optical coherence tomography standardization and validation. J. Am. Coll. Cardiol. 59, 1058–1072 (2012).
Romagnoli, E., Gatto, L. & Prati, F. The CLIMA study: assessing the risk of myocardial infarction with a new anatomical score. Eur. Heart J. Suppl. 21 (Suppl. B), B80–B83 (2019).
Prati, F. et al. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study. Eur. Heart J. 41, 383–391 (2020).
Kedhi, E. et al. Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial. Eur. Heart J. 42, 4671–4679 (2021).
Xing, L. et al. Clinical significance of lipid-rich plaque detected by optical coherence tomography: a 4-year follow-up study. J. Am. Coll. Cardiol. 69, 2502–2513 (2017).
Kubo, T. et al. Optical coherence tomography detection of vulnerable plaques at high risk of developing acute coronary syndrome. Eur. Heart J. Cardiovasc. Imaging https://doi.org/10.1093/ehjci/jeab028 (2021).
Jinnouchi, H. et al. Micro–computed tomography demonstration of multiple plaque ruptures in a single individual presenting with sudden cardiac death. Circ. Cardiovasc. Imaging 11, e008331 (2018).
Stefanadis, C., Antoniou, C., Tsiachris, D. & Pietri, P. Coronary atherosclerotic vulnerable plaque: current perspectives. J. Am. Heart Assoc. 6, e005543 (2017).
Gardner, C. M. et al. Detection of lipid core coronary plaques in autopsy specimens with a novel catheter-based near-infrared spectroscopy system. JACC Cardiovasc. Imaging 1, 638–648 (2008).
Muller, J. & Madder, R. OCT-NIRS imaging for detection of coronary plaque structure and vulnerability. Front. Cardiovasc. Med. 7, 90 (2020).
Patel, D. et al. Subsequent development of fibroatheromas with inflamed fibrous caps can be predicted by intracoronary near infrared spectroscopy. Arterioscler. Thromb. Vasc. Biol. 33, 347–353 (2013).
Schuurman, A. S. et al. Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up. Eur. Heart J. 39, 295–302 (2018).
Waksman, R. et al. Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study. Lancet 394, 1629–1637 (2019).
Waksman, R. et al. The Lipid-Rich Plaque Study of vulnerable plaques and vulnerable patients: study design and rationale. Am. Heart J. 192, 98–104 (2017).
Erlinge, D. et al. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet 397, 985–995 (2021).
Khraishah, H. & Jaffer, F. A. Intravascular molecular imaging: near-infrared fluorescence as a new frontier. Front. Cardiovasc. Med. 7, 587100 (2020).
Costopoulos, C. et al. Heterogeneity of plaque structural stress is increased in plaques leading to MACE: insights from the PROSPECT study. JACC Cardiovasc. Imaging 13, 1206–1218 (2020).
Samady, H. et al. Coronary artery wall shear stress is associated with progression and transformation of atherosclerotic plaque and arterial remodeling in patients with coronary artery disease. Circulation 124, 779–788 (2011).
Braunwald, E. Epilogue: what do clinicians expect from imagers. J. Am. Coll. Cardiol. 47, C101–C103 (2006).
Braunwald, E. Noninvasive detection of vulnerable coronary plaques. J. Am. Coll. Cardiol. 54, 58–59 (2009).
Stone, G. W. et al. Percutaneous coronary intervention for vulnerable coronary atherosclerotic plaque. J. Am. Coll. Cardiol. 76, 2289–2301 (2020).
Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387–2397 (2015).
Bhatt, D. L. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med. 380, 11–22 (2019).
Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017).
Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752–762 (2019).
Tardif, J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497–2505 (2019).
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
Navarese, E. P. et al. Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. Eur. Heart J. 42, 4638–4651 (2021).
Mehta, S. R. et al. Complete revascularization with multivessel PCI for myocardial infarction. N. Engl. J. Med. 381, 1411–1421 (2019).
Puymirat, E. et al. Multivessel PCI guided by FFR or angiography for myocardial infarction. N. Engl. J. Med. 385, 297–308 (2021).
Pinilla-Echeverri, N. et al. Nonculprit lesion plaque morphology in patients with ST-segment-elevation myocardial infarction: results from the COMPLETE trial optical coherence tomography substudys. Circ. Cardiovasc. Interv. 13, e008768 (2020).
Komukai, K. et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J. Am. Coll. Cardiol. 64, 2207–2217 (2014).
Kini, A. S. et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J. Am. Coll. Cardiol. 62, 21–29 (2013).
Nicholls, S. J. et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc. Imaging 15, 1308–1321 (2022).
Räber, L. et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA 327, 1771–1781 (2022).
Moreno, P. R. Vulnerable plaque: definition, diagnosis, and treatment. Cardiol. Clin. 28, 1–30 (2010).
Verheye, S. et al. Cryotherapy increases features of plaque stability in atherosclerotic rabbits. EuroIntervention 12, 748–756 (2016).
Wykrzykowska, J. J. et al. Plaque sealing and passivation with a mechanical self-expanding low outward force nitinol vShield device for the treatment of IVUS and OCT-derived thin cap fibroatheromas (TCFAs) in native coronary arteries: report of the pilot study vShield Evaluated at Cardiac hospital in Rotterdam for Investigation and Treatment of TCFA (SECRITT). EuroIntervention 8, 945–954 (2012).
Brugaletta, S. et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque. Atherosclerosis 221, 106–112 (2012).
Chen, H. Y. et al. Effects of stent sizing on endothelial and vessel wall stress: potential mechanisms for in-stent restenosis. J. Appl. Physiol. 106, 1686–1691 (2009).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05027984 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02316886 (2021).
Meier, B. Plaque sealing by coronary angioplasty. Heart 90, 1395–1398 (2004).
Falk, E., Nakano, M., Bentzon, J. F., Finn, A. V. & Virmani, R. Update on acute coronary syndromes: the pathologists’ view. Eur. Heart J. 34, 719–728 (2013).
Yahagi, K. et al. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat. Rev. Cardiol. 13, 79–98 (2016).
Author information
Authors and Affiliations
Contributions
P.G. and G.W.S. researched data for the article. All the authors contributed substantially to the discussion of content, wrote the manuscript, and reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
J.M. cofounded Spectrawave. G.W.S. has received speaker honoraria from Infraredx, Medtronic and Pulnovo; has served as a consultant to Abiomed, Ablative Solutions, Amgen, Ancora, Apollo Therapeutics, Cardiomech, CorFlow, Elucid Bio, Gore, HeartFlow, Impulse Dynamics, Miracor, Neovasc, Occlutech, Robocath, Shockwave, TherOx, Valfix, Vascular Dynamics, Vectorious and V-Wave; and has equity/options from Ancora, Applied Therapeutics, Aria, Biostar family of funds, Cagent, Cardiac Success, Orchestra Biomed, Spectrawave, Valfix and Xenter. G.W.S.’s daughter is an employee at Medtronic. G.W.S.’s employer, Mount Sinai Hospital, receives research support from Abbott, Abiomed, Biosense-Webster, Bioventrix, Cardiovascular Systems, Phillips, Shockwave, Vascular Dynamics and V-wave. The other authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Cardiology thanks Gerard Pasterkamp, William Wijns and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Gaba, P., Gersh, B.J., Muller, J. et al. Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research. Nat Rev Cardiol 20, 181–196 (2023). https://doi.org/10.1038/s41569-022-00769-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-022-00769-8
This article is cited by
-
Blood Flow Energy Identifies Coronary Lesions Culprit of Future Myocardial Infarction
Annals of Biomedical Engineering (2024)
-
Circular RNAs: Regulators of endothelial cell dysfunction in atherosclerosis
Journal of Molecular Medicine (2024)
-
Drug-Coated Balloon in Acute Coronary Syndromes: Ready for the Prime Time?
Current Cardiology Reports (2024)
-
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries
Nature Reviews Cardiology (2024)
-
Does Coronary Plaque Morphology Matter Beyond Plaque Burden?
Current Atherosclerosis Reports (2023)